New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists
Aineng Peng,1 Jianbo Chai,2 Haiyuan Wu,1 Bing Bai,3 Huihui Yang,1 Weizhi He,1 Yonghou Zhao2 1Heilongjiang University of Chinese Medicine, Harbin, 150040, People’s Republic of China; 2Heilongjiang Mental Hospital, Harbin, 150036, People’s Republic of China; 3Tongde Hospital of Zhejiang Province, Hang...
Main Authors: | Peng A, Chai J, Wu H, Bai B, Yang H, He W, Zhao Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2024-03-01
|
Series: | Neuropsychiatric Disease and Treatment |
Subjects: | |
Online Access: | https://www.dovepress.com/new-therapeutic-targets-and-drugs-for-schizophrenia-beyond-dopamine-d2-peer-reviewed-fulltext-article-NDT |
Similar Items
-
Novel multi-target ligands of dopamine and serotonin receptors for the treatment of schizophrenia based on indazole and piperazine scaffolds–synthesis, biological activity, and structural evaluation
by: Piotr Stępnicki, et al.
Published: (2023-12-01) -
Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
by: Davide Amato, et al.
Published: (2019-05-01) -
Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia
by: Nayla Munawar, et al.
Published: (2022-02-01) -
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
by: Albert C. Yang, et al.
Published: (2017-08-01) -
Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies. [version 1; peer review: 2 approved]
by: Stefan Leucht, et al.
Published: (2023-08-01)